Uniquity Bio Adding Matthew Hartzell as New CFO

Why This Matters: See our coverage of other industry executive team appointments and promotions here.

Uniquity Bio, a clinical-stage drug development company focusing on immunology and inflammation, welcomed Matthew Hartzell as Chief Financial Officer (CFO).

Hartzell joins as Uniquity seeks to expand to support late-stage development of its lead asset, solrikitug. This highly potent monoclonal antibody targets thymic stromal lymphopoietin (TSLP) in multiple respiratory and gastrointestinal indications with significant unmet need.

Solrikitug was in-licensed from Merck & Co., known as MSD outside the United States and Canada.

New CFO Background

Hartzell most recently served as a Vice President in the Global Healthcare Group at Goldman Sachs. There, he worked exclusively on helping biotechnology companies with holistic growth strategies, capital markets, M&A, and partnership transactions.

Previously, Hartzell was an investor covering biotechs at Casdin Capital, and an investment banker at Bank of America Merrill Lynch.

“Uniquity is approaching several big milestones, and I’m thrilled to join this talented team at this moment,” Hartzell said. “It’s been a privilege to support so many biotech companies over the years. I’m thankful to be fully focused on the promising future of Uniquity Bio and the potential patient impact of solrikitug.”

Uniquity Awaiting Trial Data

Topline data readouts are expected later in 2026 from Phase II trials of solrikitug. These tested the drug’s effectiveness in asthma, chronic obstructive pulmonary disease (COPD), and eosinophilic esophagitis (EoE).

Uniquity is also in the process of identifying bispecific and/or combination products for clinical testing. The idea behind this thinking is that if Uniquity can combine solrikitug with other inflammatory targets, it can enhance efficiency. Also, this would broaden the applicable patient population in certain indications.

Uniquity Bio is backed by Blackstone Life Sciences. Kiran Reddy, a board member of Uniquity Bio who is also Senior Managing Director of Blackstone, offered additional thoughts.

“Matt has earned a strong reputation as a trusted advisor to biotechs navigating complex strategic and financing decisions,” Reddy said. “[He] will be a tremendous asset as Uniquity continues to build value, expand strategic options, and position for future growth.”